Conclusion: Although patients with active RA and inadequate response to MTX have different therapeutic combination of biologics or small molecules options, the best relative efficacy in terms of ACR50 response after 24 weeks of treatment is for upadacitinib 15 mg/day.

REFERENCES:

Disclosure of Interests: Fabio Cacciapaglia Speakers bureau: Roche, Pfizer, Eli Lilly, MSD, UCB, BMS, Abbvie, Vincenzo Venerito: None declared, Stefano Stano: None declared, Marco Fornaro: None declared, Giuseppe Lopalco: None declared, Marco Fornaro: None declared, Giuseppe Lopalco Speakers bureau: Roche, Pfizer, Eli Lilly, MSD, UCB, BMS, Abbvie, Novartis, Fabio Cacciapaglia: Speakers bureau: Roche, Pfizer, Eli Lilly, MSD, UCB, BMS, Abbvie, Novartis, Lopalco: None declared, Marco Fornaro: None declared, Giuseppe Lomalino: None declared, Fabio Cacciapaglia: Speakers bureau: Roche, Pfizer, Eli Lilly, MSD, UCB, BMS, Abbvie, Novartis, Lomalino: None declared, Fabio Cacciapaglia: Speakers bureau: Roche, Pfizer, Eli Lilly, MSD, UCB, BMS, Abbvie, Novartis.

POS0633 DURATION OF STARTING bDMARDs ARE ALMOST 3 TIMES LONGER IN RA PATIENTS THAN Psa PATIENTS: HUR-BIO REAL LIFE RESULTS


Background: Before using biological DMARDs, EULAR suggests the use of synthetic DMARDs (especially methotrexate) for RA and PsA [1-2].

Objectives: It was aimed to evaluate the differences of disease duration and csDMARDs till first bDMARD in RA and PsA patients.

Methods: HUR-BIO (Hacettepe University Biologic Registry) is a prospective, single center database of biological treatments since 2005 and to date 2070 RA and 520 PsA patients have been recorded. Demographic, clinical and laboratory data before bDMARDs of the patients were noted. When investigating the differences between groups, the effects of gender, age, and disease duration weread-justed using two-way ANOVA and ANCOVA tests. The selection was made for the gender, age and for indifference of the relevant groups by using propensity score matching.

Results: We included 481 RA, and 482 PsA age and gender matched patients in the study. Age, gender and disease duration information were given in the Table 1. 72.8% of the RA patients were RF or anti-CCP positive. Overall, 56.3, 100% of the RA, and PsA patients first biologic therapies were anti-TNFs, respectively. All RA patients started with csDMARDs before bDMARD treatments, whereas 450 of 482 (93.4%) PsA patients. Methotrexate was the anchor csDMARD for both diseases. RA patients more frequently used all csDMARDs included methotrexate, leflunomide, sulfasalazine hydroxychloroquine and corticosteroids as well. Median disease duration till bDMARD treatments in RA and PsA patients were 55 and 18.5 months respectively (p<0.001) (Table 1).

Table 1. Demographic characteristics and csDMARDs before first bDMARD

<table>
<thead>
<tr>
<th>RA (n=481)</th>
<th>PsA (n=482)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female, n (%)</strong></td>
<td>319 (66.3)</td>
<td>332 (68.9)</td>
</tr>
<tr>
<td><strong>Age, years (mean±SD)</strong></td>
<td>48.2 ± 13.5</td>
<td>47.4 ± 12.2</td>
</tr>
<tr>
<td><strong>Disease duration, years</strong></td>
<td>10 (6-16)</td>
<td>7 (3-12)</td>
</tr>
<tr>
<td><strong>Symptom duration before diagnosis, years</strong></td>
<td>0 (0-1)</td>
<td>1 (0-4)</td>
</tr>
<tr>
<td><strong>The period of time between diagnosis and bDMARD initiation, months</strong></td>
<td>55 (24-115)</td>
<td>18.5 (8-58)</td>
</tr>
<tr>
<td><strong>The period of time between symptoms and bDMARD initiation, months</strong></td>
<td>70 (35-151)</td>
<td>48 (20-124)</td>
</tr>
<tr>
<td><strong>Methotrexate Ever n (%)</strong></td>
<td>400 (83.3)</td>
<td>373 (77.5)</td>
</tr>
<tr>
<td><strong>Ever n (%)</strong></td>
<td>251 (52.2)</td>
<td>230 (47.7)</td>
</tr>
<tr>
<td><strong>Hydroxychloroquine sulfate Ever n (%)</strong></td>
<td>292 (60.8)</td>
<td>170 (35.3)</td>
</tr>
<tr>
<td><strong>Just before bDMARD initiation n (%)</strong></td>
<td>262 (54.5)</td>
<td>99 (20.5)</td>
</tr>
<tr>
<td><strong>Leflunomide Ever n (%)</strong></td>
<td>237 (49.4)</td>
<td>129 (26.8)</td>
</tr>
<tr>
<td><strong>Just before bDMARD initiation n (%)</strong></td>
<td>160 (33.3)</td>
<td>96 (19.9)</td>
</tr>
<tr>
<td><strong>Sulphasalazine Ever n (%)</strong></td>
<td>353 (73.5)</td>
<td>265 (55.1)</td>
</tr>
<tr>
<td><strong>Just before bDMARD initiation n (%)</strong></td>
<td>156 (32.4)</td>
<td>146 (30.3)</td>
</tr>
<tr>
<td><strong>Corticosteroids Ever n (%)</strong></td>
<td>419 (87.3)</td>
<td>281 (58.4)</td>
</tr>
<tr>
<td><strong>Just before bDMARD initiation n (%)</strong></td>
<td>335 (69.6)</td>
<td>187 (38.8)</td>
</tr>
</tbody>
</table>

Conclusion: According to HUR-BIO real life data, for inflammatory arthritis patients who started bDMARDs, the periods of time between diagnosis and bDMARDs were more reasonable (18 months) in PsA patients than RA patient’s periods which were approximately three times longer. RA patients were used much more and longer duration of csDMARDs. This explicit distinction may be explained by synthetic DMARDs on activity differences between the RA and PsA.

REFERENCES:

Figure 1. The hospital separations and total drugs use patterns of RA in 1995-2014 in Western Australia.

Acknowledgements: Supported by an Australian Government Research Training Program PhD Scholarship at the University of Western Australia.

**Disclosure of Interests: None declared**

DOI: 10.1136/annrheumdis-2021-eular.3283

POS0634  
**DO BIOLOGICS IMPROVE FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS?**

A. Fazaaz1, H. Bousbais1, K. Quenniche1, S. Miladi1, M. Sellami1, L. Souabni1, S. Kassab1, S. Chekili1, K. Ben Abdelghani1, A. Lataf1,1 Mongi Slim University Hospital, Rheumatology, Sidi Daoud, Tunisia

**Background:** Fatigue is a significant issue in rheumatoid arthritis (RA) with no accepted evidence-based management guidelines. Several studies suggested that biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) have a direct role on fatigue in RA.

**Objectives:** This study aimed to compare fatigue between patients treated with bDMARDs and conventional synthetic Disease Modifying Anti-Rheumatic Drugs (cs DMARDs).

**Methods:** We conducted a longitudinal study including patients with RA (ACR/EULAR 2010). Patients with other acute or chronic diseases that may induce fatigue (such as cancer, infection or depression) were excluded. Demographic data and the following disease-related parameters were collected: pain Visual Analog Scale (VAS), General Fatigue Assessment (GPA), tender joint count (TJC), swollen joint count (SJC), Erythrocyte Sedimentation Rate (ESR), C Protein Reactive (CRP), Disease Activity Score 28 (DAS28), Health Assessment Questionnaire (HAQ) and DMARDs used. Fatigue was assessed at baseline (T0), at 6 months (T6) and at 12 months (T12) using the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) which is a short 13-item questionnaire validated in RA. The score FACIT-F ranges between 0 and 52. Fatigue was considered mild if the FACIT-F score was ≥40, moderate if 20≤FACIT-F<40 and severe if 0≤FACIT-F<20. A p value inferior to 0.05 was considered significant.

**Results:** We included 100 RA patients (84 women and 16 men) with a mean age of 49.5±10 years old [18-65]. The mean disease duration was 8.7±3 months [1-360]. The mean pain VAS was 49.3±100 and the mean GPA was 47.8±100. The mean TJC and SJC were 5.3 [0-36] and 1 [0-9] respectively. The mean levels of ESR and CRP were 38.1±10 [10-120] and 10.8 [2-61] respectively. The mean DAS28 ESR was 3.68 [1.90-8.33] and the mean HAQ score was 0.9 [0-2.75].

Eighty-three percent of patients used cs DMARDs: Methotrexate (n=96), sulphasalazine (n=28), leflunomide (n=21), and hydroxycloquinone (n=12); bDMARDs were prescribed in 17% of patients: Rituximab (n=10), Infliximab (n=9), and Etanercept (n=5). At baseline, the mean FACIT-F score was 27.1 [0-51]. Moderate fatigue was noted in 57% of cases and severe fatigue in 26% of cases. Patients on cs DMARDs had a lower FACIT-F score when compared to patients on bDMARDs (25.8±28.41) but the difference was not statistically significant (p=0.630).

The mean FACIT-F score was 27.41 in bDMARDs patients versus 28.60 in cs DMARDs patients (p=0.947) at T6, and 32.35 versus 33.65 respectively at T12 (p=0.695). The mean delta FACIT-F was 2.18 in bDMARDs patients versus 2.73 in cs DMARDs patients between T6 and T0 (p=0.815), and 3.94 versus 7.2 respectively between T12 and T0 (p=0.807). When considering all patients, a significant positive correlation was noted between delta FACIT-F and delta DAS28 at T6 (r=0.418, p<0.001) and at T12 (r=0.339, p<0.001).

**Conclusion:** RA patients treated with bDMARDs didn’t show significant improvement of fatigue in comparison with those treated with cs DMARDs. Further studies are needed to determine if biologics improve fatigue, and whether the improvement results from a direct action on fatigue or indirectly through reduction in disease activity.

**Disclosure of Interests: None declared**

DOI: 10.1136/annrheumdis-2021-eular.3341

POS0635  
**COMPARING THE ULTRASONOGRAPHIC EVALUATION IN PATIENTS WITH JAPANESE RHEUMATOID ARTHRITIS BETWEEN BARICITINIB AND TNF ANTAGONIST THERAPY**

Y. Kanyama1, A. Nagata2, M. Shimotake2, F. Miyachi2, K. Fujita2, M. Koyama2, S. Uno2,1 Toyota Kosei Hospital, Orthopedic Surgery and Rheumatology, Toyota, Japan; 2Toyota Kosei Hospital, Clinical Technology, Toyota, Japan

**Background:** Baricitinib (BAR) and TNF antagonist are the important therapeutic agent for the treatment of rheumatoid arthritis. However, there are still few studies of improvement of ultrasonographic findings in RA treated comparison with BAR and TNF.

**Objectives:** To evaluate the clinical efficacy of BAR and TNF therapy patients with rheumatoid arthritis (RA) using ultrasonography (US).

**Methods:** Participants comprised 16 and 45 Japanese RA patients who had recently received BAR and TNF. All patients with a diagnosis of RA according to the 2010 ACR/EULAR criteria. Patients underwent clinical and laboratory assessments every 4 weeks from baseline to 24 weeks, and US assessments at baseline, 4, 12 and 24 weeks. Gray scale (GS) and power doppler (PD) signals were scored using a semi-quantitative scale from 0 to 3 at 26 (0-78) synovial sites (22 joints) in the following joints: bilateral first to fifth metacarpophalangeal (MCP) joints (dorsal recess); first interphalangeal (IP) and second to fifth proximal interphalangeal (PIP) (dorsal recess) joints; and the wrists (dorsal radial, median and ulnar). We evaluated the improvement of GS and PD score from baseline to week 24.

**Results:** In the patients undergoing BAR (n=16) and TNF (n=45), the mean age was 55.9±5.6 years old (p=0.682), disease duration was 10.2±6.1 years (p<0.094), the rate of MTX use was 75% vs 89% (p=0.346), the mean MTX dose was 9.3±10.2 mg/w (p=0.443), the rate of ACPO positive was 94% vs 82% (p=0.476), DAS28-ESR was 4.25±4.61 (p=0.289), CDAI was 15.8±18.5 (p=0.210), GS score was 21.6±16.3 (p=0.436) and PD score was 15.0±9.5 (p=0.260). The degree of improvement of changes in GS and PD score after 4, 12 and 24 weeks was as follows: GS: -72 vs -3.7 (p=0.288) and PD: -76 vs -2.3 (p=0.158) after 4 weeks, GS: -10.9 vs -5.0 (p=0.161) and PD: -9.2 vs -3.8 (p=0.049) after 12 weeks, GS: -12.9 vs -6.1 (p=0.485) and PD: -113 vs -5.7 (p=0.062) after 24 weeks between BAR and TNF (Fig1, 2).

The improvement rate of changes in GS and PD score after 4, 12 and 24 weeks were as follows: GS: -23.8% vs -11.6% (p=0.960) and PD: -30.3% vs -16.5% (p=0.343) after 4 weeks, GS: -39.6% vs -15.6% (p=0.129) and PD: -47.1% vs -30.8% (p=0.210) after 12 weeks, GS: -52.2% vs -22.2% (p=0.248) and PD: -77.1% vs -50.1% (p=0.048) after 24 weeks between BAR and TNF.

**Conclusion:** The present study provides evidence supporting both the BAR and TNF therapy showed improvement effect over time, but in a comparison between BAR and TNF, the PD score of BAR showed a significant improvement effect compared to TNF at 12 and 24 weeks. It was suggested that BAR may improve inflammatory synovitis earlier compared to TNF.

**Disclosure of Interests: None declared**

DOI: 10.1136/annrheumdis-2021-eular.3483